Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine

Imagem de Miniatura
Arquivos
art_APOSTOLICO_PolyIC_Potentiates_T_Cell_Immunity_to_a_Dendritic_2019.PDF (4.27 MB)
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
APOSTOLICO, Juliana de Souza
LUNARDELLI, Victoria Alves Santos
YAMAMOTO, Marcio Massao
CUNHA-NETO, Edecio
BOSCARDIN, Silvia Beatriz
ROSA, Daniela Santoro
Citação
FRONTIERS IN IMMUNOLOGY, v.10, article ID 843, 12p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cellular immune responses are implicated in resistance to HIV and have been considered for the development of an effective vaccine. Despite their safety profile, subunit vaccines need to be delivered combined with an adjuvant. In the last years, in vivo antigen targeting to dendritic cells (DCs) using chimeric monoclonal antibodies (mAb) against the DC endocytic receptor DEC205/CD205 was shown to support long-term T cell immunity. Here, we evaluated the ability of different adjuvants to modulate specific cellular immune response when eight CD4(+) HIV-derived epitopes (HIVBr8) were targeted to DEC205(+) DCs in vivo. Immunization with two doses of alpha DECHIVBr8 mAb along with poly(I:C) induced Th1 cytokine production and higher frequency of HIV-specific polyfunctional and long-lived T cells than MPL or CpG ODN-assisted immunization. Although each adjuvant elicited responses against the 8 epitopes present in the vaccine, the magnitude of the T cell response was higher in the presence of poly(I:C). Moreover, poly(I:C) up regulated the expression of costimulatory molecules in both cDC1 and cDC2 DCs subsets. In summary, the use of poly(I:C) in a vaccine formulation that targets multiple epitopes to the DEC205 receptor improved the potency and the quality of HIV-specific responses when compared to other vaccine-adjuvant formulations. This study highlights the importance of the rational selection of antigen/adjuvant combination to potentiate the desired immune responses.
Palavras-chave
HIV, multiepitope vaccine, dendritic cell targeting, DEC205, adjuvants
URI
https://observatorio.fm.usp.br/handle/OPI/31586
Referências
  1. Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
  2. Amorim KNS, 2016, SCI REP-UK, V6, DOI 10.1038/srep39250
  3. Antonialli R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01727
  4. Apostolico JD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00101
  5. Apostolico JD, 2016, J IMMUNOL RES, DOI 10.1155/2016/1459394
  6. Apostolico JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145637
  7. Apostolopoulos V, 2013, J DRUG DELIV, DOI 10.1155/2013/869718
  8. Barry M, 2007, EXPERT OPIN BIOL TH, V7, P1731, DOI 10.1517/14712598.7.11.1731
  9. Baumgartner CK, 2010, IMMUNOLOGY, V130, P16, DOI 10.1111/j.1365-2567.2010.03265.x
  10. Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
  11. Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639
  12. Caminschi I, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23128
  13. Cheong C, 2010, BLOOD, V116, P3828, DOI 10.1182/blood-2010-06-288068
  14. Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
  15. Cohn L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00255
  16. Curtsinger JM, 2005, J IMMUNOL, V174, P4465, DOI 10.4049/jimmunol.174.8.4465
  17. Dhodapkar MV, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008068
  18. Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080
  19. Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797
  20. Flynn BJ, 2011, P NATL ACAD SCI USA, V108, P7131, DOI 10.1073/pnas.1103869108
  21. Gandhapudi SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056855
  22. Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
  23. Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
  24. Griffiths EA, 2018, CLIN CANCER RES, V24, P1019, DOI 10.1158/1078-0432.CCR-17-1792
  25. Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015
  26. Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712
  27. Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072
  28. Gutjahr A, 2016, TRENDS IMMUNOL, V37, P716, DOI 10.1016/j.it.2016.08.005
  29. Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
  30. Havenar-Daughton C, 2006, J IMMUNOL, V176, P3315, DOI 10.4049/jimmunol.176.6.3315
  31. Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769
  32. Hemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059
  33. Hemmi Hiroaki, 2005, V86, P120
  34. Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
  35. Idoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108
  36. INABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109
  37. Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123
  38. Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010
  39. Kannanganat S, 2007, J VIROL, V81, P12071, DOI 10.1128/JVI.01261-07
  40. Kastenmuller W, 2014, NAT REV IMMUNOL, V14, P705, DOI 10.1038/nri3727
  41. KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981
  42. Kwissa M, 2007, EXPERT REV VACCINES, V6, P673, DOI 10.1586/14760584.6.5.673
  43. Kwissa M, 2012, BLOOD, V119, P2044, DOI 10.1182/blood-2011-10-388579
  44. Lahoud MH, 2012, P NATL ACAD SCI USA, V109, P16270, DOI 10.1073/pnas.1208796109
  45. Lakhrif Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00317
  46. Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247
  47. Lopez-Bravo M, 2008, IMMUNITY, V29, P343, DOI 10.1016/j.immuni.2008.08.008
  48. Macri C, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.6
  49. Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521
  50. Martin M, 2003, INFECT IMMUN, V71, P2498, DOI 10.1128/IAI.71.5.2498-2507.2003
  51. Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085
  52. Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963
  53. McElrath MJ, 2017, CURR OPIN HIV AIDS, V12, P278, DOI 10.1097/COH.0000000000000365
  54. McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
  55. Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950
  56. Mutwiri GK, 2004, J CONTROL RELEASE, V97, P1, DOI 10.1016/j.jcornel.2004.02.022
  57. Park CG, 2014, CLIN EXP VACCINE RES, V3, P149, DOI 10.7774/cevr.2014.3.2.149
  58. Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
  59. Rampazo EV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117778
  60. Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
  61. Ruane D, 2016, MUCOSAL IMMUNOL, V9, P1340, DOI 10.1038/mi.2015.133
  62. Sahay B., 2017, J CLIN CELL IMMUNOL, V8, P518, DOI [10.4172/2155-9899.1000518, DOI 10.4172/2155-9899.1000518]
  63. Sarkar S, 2007, J IMMUNOL, V179, P6704, DOI 10.4049/jimmunol.179.10.6704
  64. Shirota H, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P163, DOI 10.1016/B978-0-12-804019-5.00009-8
  65. Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996
  66. Silva-Sanchez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124828
  67. Steinman RM, 2010, IMMUNOL REV, V234, P5, DOI 10.1111/j.0105-2896.2009.00888.x
  68. Teixeira D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00177
  69. Tewari K, 2010, VACCINE, V28, P7256, DOI 10.1016/j.vaccine.2010.08.098
  70. Thompson BS, 2005, J LEUKOCYTE BIOL, V78, P1273, DOI 10.1189/jlb.0305172
  71. Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005
  72. Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x
  73. Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105
  74. Villadangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103
  75. Wang M, 2009, CLIN EXP IMMUNOL, V155, P441, DOI 10.1111/j.1365-2249.2008.03856.x
  76. Wiesel M, 2012, EUR J IMMUNOL, V42, P320, DOI 10.1002/eji.201142091
  77. Wiesel M, 2011, J IMMUNOL, V186, P754, DOI 10.4049/jimmunol.1003166
  78. Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
  79. 2010, EUR J IMMUNOL, V40, P2791, DOI 10.1002/EJI.201040511
  80. 2004, J EXP MED, V199, P815, DOI 10.1084/JEM.20032220

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - ODS/03